All Times in Eastern Standard Time (EST)
Attendees should have received a login to an Agenda with recordings. Please contact us if you have not received this link.
11:00 AM Keynote: Opening Doors to US-Based Cannabis Research
Dr. Sue Sisley, The Scottsdale Research Institute
Dr. Sisley will provide a deep dive into recent PTSD studies as well as an update on the lawsuit to force DEA to allow researchers to source cannabis through cultivators other than the monopoly held for decades by the University of Mississippi. Dr. Sisley will then lay out a roadmap for how a molecule can make the journey to medicine.
11:30 AM Medical Cannabis Treatments and Trials Update
Dr. Stacia Woodcock, Director of Education – International Research Center on Cannabis and Health
Dr. Woodcock reveals what Pharmacists are seeing and what the data says about dosing and treatments making an impact.
12:00 PM Medical Cannabis Patches – the Future of Continuous Dose and Delivery
Dr. Anne Ladegaard Skov, Technical University of Denmark, spinout Silease
Learn how Silease has developed novel cannabinoid patches based on new topical delivery technology recognised by leading international companies in wound care and cosmetics. Silease delivery device can provide precise and continuous dosing over extended period of time with the possibility to adjust release of cannabinoids.
12:30 PM Insights on the Patient Experience
Paula Gordy, Patient Consultant/Dispensary Associate – Curaleaf
Join Ms. Gordy in a live Q and A entitled Insights on the Patient Experience. She’ll share an overview of becoming a patient in New Jersey’s MMP and how the dispensary team helps patients navigate the program. She welcomes any questions that you have regarding the patient experience!
1:00 PM – 2:00 PM Virtual Break/Networking
2:00 PM Harnessing Synthetic Biology to deliver Improved and Novel Cannabinoids for Pharmaceutical industry
Nethaji Gallage, CEO – Octarine
Learn how Dr. Nethaji Gallage, CEO of the Denmark-based startup Octarine Bio is innovating by developing a biosynthetic platform for cannabinoid and psilocybin derivatives using microbial fermentation. Find out why Octarine’s mission to improve the health and well-being of people worldwide drives them to engineer microorganisms to produce a range of natural and novel cannabinoid and psilocybin derived molecules with improved pharmacokinetic and therapeutic properties. https://octarinebio.com/
2:30 PM Pharmacogenomic Studies Update on Medical Cannabis
Jahan Marcu, Editor in Chief of the American Journal of Endocannabinoid Medicine
This presentation will discuss PGx testing for cannabis and potential impacts on commonly prescribed pharmaceuticals, diving into the pharmacokinetics and pharmacogenomics involving the latest results in medical cannabis studies.
The therapeutic applications of medical cannabis and cannabinoid drugs is controversial, however the number of medical conditions in which cannabinoids and cannabis have shown promise as therapeutic treatments is expanding. The occurrence of side effects from cannabinoids is still a concern, especially with the wide variability in drug levels and response that has been observed. This is compounded by possible interactions with prescription drugs. Application of pharmacogenomics (PGx) and knowledge of drug-drug interactions could help patients and doctors navigate the complexities of combining prescription drugs and cannabis compounds. Genetic variants in several drug metabolizing enzymes may impact response to cannabinoids, including CYP3A4, CYP2C9, and CYP2C19. Furthermore, drug interactions caused by cannabinoids may also be mediated by drug metabolizing enzymes (e.g. CYP2C9, CYP2D6, CYP2B6, CYP1A1) and possibly drug transporters such as ABCB1. Understanding how commonly prescribed drugs and cannabinoids interact could help reduce risks associated with polydrug regimens, and possibly predict adverse reactions to cannabis and susceptibility to Cannabis Use Disorder.
3:00 PM Global Cannabis Research Landscape
Dr. Emmanuel Onaivi, Professor – William Paterson University
Professor Onaivi shares what it happening and focusing on key areas of cannabis research with a view of global activity and research accelerating.
3:30 PM – 5:00 PM Virtual Break/Networking
5:00 PM The Future of Precision Cannabinoid Therapeutics
Len May, CEO – Endocanna Health
Endocanna CEO Len May discusses how a range of people with different genotype profiles have different outcomes and experiences and shares patient case studies.
5:30 PM Medical Cannabis Education: Focus on the Evidence
Dr. Sandra Carrillo, President of The Colombian Medical Association for Cannabis Medicine
Learn about medical cannabis and the evidence surrounding patient use and efficacy. Dr Sandra Carrillo will present case examples and experiences to provide a foundation for understanding how medical education is reshaping how medical professionals are learning about cannabinoids and treatments.
6:00 PM Future of Cultivation for Medical Cannabis
Professor Mike Dixon, Head of Cannabis Centre of Excellence – University of Guelph
Dr. Dixon will dive into data and results of different cannabis focused experiments to create consistent reproducible cannabinoids with recent studies and data on controlled environment impact on consistency.
6:30 PM Panel: Breaking down Barriers to Cannabis Investment
Moderator: Keith Bisogno, Event Chair
– Barbara Koz Paley, Founder and Chair – Balco
– Alice Globus, Partner, Chief Financial Officer, & Investment Committee Chair – Globus Growth
– Michael Prytz, Senior Advisor – Ministry of Foreign Affairs of Denmark
– Rob O’Brien, Founder of Supra Research, Industry Investor
Hear our expert panel discuss where and why investors are getting behind medical cannabis and how research, science and industry professionals can tap into the investment community to raise capital.
Questions to help Answer for audience:
- Where are there viable sources for research or innovation capital and investment? Is the US a place?
- Are there traditional scientific sources of funding opening up – anywhere in the world?
- How can researchers be effective in clearing a path to potential investors and sources of capital?
- What are any tips to scientists and clinicians to get their ideas off the ground and find funding?
- What are the areas of the cannabis and medical cannabis supply chain where researchers can help innovate and find a path to business success?
- What if any mistakes or trips and traps can researchers avoid to get farther faster?